MIRXES-B (02629) surged over 35% during intraday trading, reaching a record high of HK$59.5, representing a gain of more than 150% from its IPO price of HK$23.3. As of press time, the stock was trading up 24.43% at HK$54.75 with turnover of HK$566 million.

On the news front, according to an August 22 announcement by Hang Seng Indexes Company, Mirxes has been included in the Hang Seng Composite Index. The related changes took effect on September 8, and the company has officially become a constituent of Hong Kong Stock Connect under the Shanghai-Hong Kong Stock Connect program.

According to public information, Mirxes is a Singapore-headquartered microRNA (miRNA) technology company dedicated to making disease screening and diagnostic solutions accessible across key Asian markets. As of the latest practicable date, the group has one core product (GASTROClear™), two other commercialized products (LUNGClear™ and Fortitude™), and six candidate products in preclinical stages.

The group's core product, GASTROClear™, is a blood-based miRNA test panel composed of 12 miRNA biomarkers for gastric cancer screening. The product was successfully commercialized in Singapore after obtaining a Class C in vitro diagnostic (IVD) certificate from Singapore's Health Sciences Authority (HSA) in May 2019.